Should the commonly accepted definition of “unprovoked venous thrombembolism” be revisited?

Walter Ageno; Alessandro Squizzato; Francesco Dentali

doi:10.1160/TH12-03-0164

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2012; 107(05): 806-807
DOI: 10.1160/TH12-03-0164

Invited Editorial Focus

Schattauer GmbH

Should the commonly accepted definition of “unprovoked venous thrombembolism” be revisited?

Walter Ageno

¹Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

,

Alessandro Squizzato

¹Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

,

Francesco Dentali

¹Research Center on Thromboembolic Disorders and Antithrombotic Therapies, Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 White RH. The epidemiology of venous thromboembolism. Circulation. 2003 107. I-4-I-8.
2 Prandoni P, Lensing AWA, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
3 Heit JA, Silverstein MD, Mohr DN. et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159: 445-453.
4 Iorio A, Kearon C, Filippucci E. et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170: 1710-1716.
5 Hutten BA, Prins MH, Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2003; 18: 3078-3083.
6 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease. Chest 2012; 141: e419S-e494S.
7 Heit JA, O’Fallon WM, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
8 Ageno W, Agnelli G, Imberti D. et al. Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the MASTER registry. Intern Emerg Med. 2011 epub ahead of print.
9 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2012; 363: 2499-2510.
10 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients. Haematologica 2007; 92: 199-205.
11 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
12 Hansson PO, Welin L, Tibblin G. et al. Deep vein thrombosis and pulmonary embolism in the general population. The Study of Men Born in 1913. Arch Intern Med 1997; 157: 1665-1670.
13 Ageno W, Becattini C, Brighton T. et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.
14 Ageno W, Prandoni P, Romualdi E. et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 04: 1914-1918.
15 Severinsen MT, Kristensen SR, Johnsen SP. et al. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009; 07: 1297-1303.
16 Squizzato A, Romualdi E, Büller HR. et al. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92: 2415-2420.
17 Squizzato A, Romualdi E, Piantanida E. et al. Sub-clinical hypothyroidism and deep venous thrombosis. A pilot, cross-sectional study. Thromb Haemost 2007; 97: 803-806.
18 Segal JB, Brotman DJ, Necochea AJ. et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. J Am Med Assoc 2009; 301: 2472-2485.
19 Tichelaar YIGV, Kluin-Nelemans JC, Meijer K. Infections and inflammatory diseases as risk factors for venous thrombosis, a systematic review. Thromb Haemost 2012; 107: 827-837.
20 Dentali F, Nicolini E, Ageno W. Venous and arterial thrombosis associated with HIV infection. Semin Thromb Hemost. 2012 epub ahead of print.
21 Squizzato A, Gerdes VE, Büller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005; 93: 403-410.
22 Eichinger S, Hron G, Bialonczyk C. et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-1683.
23 Novacek G, Weltermann A, Sobala A. et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139: 779-787.